Finance

Lists
FULC:NASDAQ
Fulcrum Therapeutics Inc
၃.၇၀ US$
+၀.၅၄%
(+၀.၀၂၀) 1D
၃.၇၀ US$
-၀.၀၂% (-၀.၀၀၀၇၀)
After hours
Closed: နို ၆, GMT-၅ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FULC...
Open
၃.၆၇ US$
High
၃.၇၃ US$
Low
၃.၆၇ US$
Mkt. cap
၂၈.၂၃ ကုဋေ
Avg. vol.
၁.၄၃ သန်း
Volume
၈.၉၂ သိန်း
52-wk high
၁၅.၇၄ US$
52-wk low
၂.၈၃ US$
EPS
-၁.၂၁ US$
Beta
၂.၈၂
Shares outstanding
၇.၆၃ ကုဋေ
No. of employees
၉
Open
၃.၆၇ US$
High
၃.၇၃ US$
Low
၃.၆၇ US$
Mkt. cap
၂၈.၂၃ ကုဋေ
Avg. vol.
၁.၄၃ သန်း
Volume
၈.၉၂ သိန်း
52-wk high
၁၅.၇၄ US$
52-wk low
၂.၈၃ US$
EPS
-၁.၂၁ US$
Beta
၂.၈၂
Shares outstanding
၇.၆၃ ကုဋေ
No. of employees
၉
News stories
From web sources and news partners
Benzinga
Benzinga
·
ပြီးခဲ့သည့် ၁ နာရီ
Dow Jones and S&P 500 Outlook: Stock Market News To Watch This Week
Bloomberg.com
Bloomberg.com
·
ပြီးခဲ့သည့် ၁ ရက်
Wall Street Strategists Call Stock Rout a Fresh Reason to Buy
Investor's Business Daily
Investor's Business Daily
·
ပြီးခဲ့သည့် ၃ နာရီ
Dow Jones Futures Loom With Market Damaged, Big Winners Broken; Apple, Amazon, Microsoft Strong
About Fulcrum Therapeutics Inc
CEO-
Employees၉
Founded၂၀၁၅
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 1 analyst giving stock ratings to FULC in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for FULC in the last 3 months
Highest
Current ၃.၇၀ US$
(-၁၀၀.၀၀%)
Average
(-၁၀၀.၀၀%)
Lowest
(-၁၀၀.၀၀%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gregory Renza
Truist Financial
Hold
Maintained
-
-
08/18/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
၃.၀၀ US$
-၁၈.၉%
08/07/2026
Anupam Rama
J.P. Morgan
Sell
Downgraded
-
-
06/02/2026
Andrew Fein
H.C. Wainwright
Hold
Downgraded
၃.၀၀ US$
-၁၈.၉%
06/02/2026
Joseph Schwartz
Leerink Partners
Hold
Downgraded
၄.၀၀ US$
+၈.၁%
06/02/2026
Edward Tenthoff
Piper Sandler
Sell
Downgraded
၃.၀၀ US$
-၁၈.၉%
06/02/2026
James Condulis
Stifel Nicolaus
Hold
Downgraded
၃.၀၀ US$
-၁၈.၉%
06/02/2026
Luca Issi
RBC Capital
Hold
Maintained
၄.၀၀ US$
+၈.၁%
06/02/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
၁၅.၀၀ US$
+၃၀၅.၄%
04/28/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
၂၄.၀၀ US$
+၅၄၈.၆%
03/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
၁.၄၃ ကုဋေ
၁.၅၄ ကုဋေ
-
-
Cost of revenue
၁.၄၃ ကုဋေ
၁.၅၄ ကုဋေ
-
-
Research and development expenses
-
-
၁.၄၁ ကုဋေ
၁.၂၄ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၇.၅၆ သန်း
၇.၂၈ သန်း
၈.၁၀ သန်း
၇.၄၆ သန်း
Operating expense
၇.၅၆ သန်း
၇.၂၈ သန်း
၂.၂၂ ကုဋေ
၁.၉၉ ကုဋေ
Total operating expenses
၂.၁၉ ကုဋေ
၂.၂၇ ကုဋေ
၂.၂၂ ကုဋေ
၁.၉၉ ကုဋေ
Operating income
-၂.၁၉ ကုဋေ
-၂.၂၇ ကုဋေ
-၂.၂၂ ကုဋေ
-၁.၉၉ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၁.၉၆ ကုဋေ
-၂.၀၃ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၆၂ ကုဋေ
EBT excluding unusual items
-၁.၉၆ ကုဋေ
-၂.၀၃ ကုဋေ
-၁.၈၉ ကုဋေ
-၁.၆၈ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၁.၉၆ ကုဋေ
-၂.၀၃ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၆၂ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၃၁
-၀.၃၁
-၀.၂၅
-၀.၂၂
Interest and investment income
၂.၂၆ သန်း
၂.၃၆ သန်း
၃.၃၀ သန်း
၃.၁၃ သန်း
Interest expense
-
-
-
-
Net interest expenses
၂.၂၆ သန်း
၂.၃၆ သန်း
၃.၃၀ သန်း
၃.၁၃ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၂.၁၅ ကုဋေ
-၂.၂၃ ကုဋေ
-၂.၁၈ ကုဋေ
-၁.၉၇ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ